CUPRIOR (JACE Pharma Pty Ltd)
Product name
CUPRIOR
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
212 (255 working days)
Active ingredients
trientine tetrahydrochloride
Registration type
NCE/NBE
Indication
CUPRIOR (film-coated tablet) is indicated for the treatment of Wilson's disease in adults, adolescents and children≥5 years intolerant to D-penicillamine therapy.
Registration process
Orphan drug
Sponsors receive a fee waiver to help bring medicines for a small population to market.